Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Executive Summary
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say
You may also be interested in...
Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA
Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA
Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA
Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.